COSMOS Pharmaceutical Corporation [3349.T]
TOKYO, Apr 13 (Pulse News Wire) – Cosmos Pharmaceutical Corporation (3349.T) reported consolidated results for Q3 FY2026 (ending May 2026). Revenue was ¥810 billion (+7.7% YoY).
Operating profit was ¥48,578 million (+4.3%). net profit attributable to shareholders was ¥33,865 million (+0.3%).
Total assets stood at ¥550 billion with an equity ratio of 50.2%. The company declared an annual dividend of ¥38 per share.
The full-year forecast for the current fiscal year is revenue of ¥1.1 trillion (+4.5%).
Financial results — FY2026/5 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥810,380M | +7.7% |
| Operating profit | ¥48,578M | +4.3% |
| Net profit | ¥33,865M | +0.3% |
Next period forecast
Revenue
¥1,057,000M
+4.5%Op. profit
¥40,500M
+0.2%Net profit
¥31,000M
+0.1%Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.